Tarsus Pharmaceuticals announced plans to acquire Alkeus Pharmaceuticals, including its emerging oral treatment for Stargardt disease, gildeuretinol (ALK-001), in a deal valued up to $800 million. Stargardt disease is the most common form of inherited macular degeneration and is often diagnosed in children or teens. There are no current treatments.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Foundation Fighting Blindness. Innehållet i podden är skapat av Foundation Fighting Blindness och inte av, eller tillsammans med, Poddtoppen.